|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Cure_Duchenne_Ventures
gptkb:Tessera_Therapeutics
|
|
gptkbp:ceo
|
gptkb:Stanley_T._Crooke
|
|
gptkbp:clinical_trial
|
gptkb:Hemophilia_A
gptkb:Sickle_Cell_Disease
gptkb:Duchenne_Muscular_Dystrophy
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaboration
|
gptkb:Harvard_University
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
|
|
gptkbp:employees
|
200+
|
|
gptkbp:focus
|
gptkb:gene_therapy
|
|
gptkbp:founded
|
gptkb:1995
|
|
gptkbp:founder
|
gptkb:Edward_Lanphier
|
|
gptkbp:headquarters
|
gptkb:Richmond,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SGMO
|
|
gptkbp:invention
|
gene editing technologies
|
|
gptkbp:investment
|
Institutional investors
Venture capital firms
|
|
gptkbp:notable_products
|
gptkb:SB-318
ST-400
SB-525
SB-913
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:Editas_Medicine
gptkb:Astra_Zeneca
gptkb:Cure_Duchenne_Foundation
gptkb:Cure_Duchenne_Ventures
gptkb:Bristol-Myers_Squibb
gptkb:Intellia_Therapeutics
gptkb:Pfizer
gptkb:Regeneron_Pharmaceuticals
gptkb:Biogen
gptkb:Roche
gptkb:Duchenne_Alliance
gptkb:Amgen
gptkb:CRISPR_Therapeutics
gptkb:Vertex_Pharmaceuticals
gptkb:Celgene
gptkb:Cure_Duchenne
gptkb:Sarepta_Therapeutics
gptkb:Duchenne_Parent_Project
gptkb:Novartis
|
|
gptkbp:research_focus
|
gptkb:Oncology
genetic disorders
infectious diseases
|
|
gptkbp:revenue
|
$50 million (2020)
|
|
gptkbp:stock_symbol
|
gptkb:SGMO
|
|
gptkbp:technology
|
zinc finger nucleases
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.sangamo.com
|
|
gptkbp:bfsParent
|
gptkb:Sangamo_Therapeutics
|
|
gptkbp:bfsLayer
|
4
|